Evidence map›Paper›PMID 33704192›Full record

ArticleCurrent oncology (Toronto, Ont.)2020

Reevaluating Patient Eligibility for Inotuzumab Ozogamicin Based on CD22 Expression: Is Dim Expression Sufficient?

Warren Fingrut, Wendy Davis, Eric McGinnis, Karen Dallas, Khaled Ramadan, Hayley Merkeley, Heather Leitch, Yasser Abou Mourad, Ryan D Cassaday, Camilla Ross and 1 more

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Current oncology (Toronto, Ont.), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.7field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 2 countries.

Warren FingrutFaculty of Medicine, University of British Columbia, Vancouver, BC V6T 1Z4, Canada.ORCID 0000-0002-5017-1583
Wendy DavisFaculty of Medicine, University of British Columbia, Vancouver, BC V6T 1Z4, Canada.
Eric McGinnisFaculty of Medicine, University of British Columbia, Vancouver, BC V6T 1Z4, Canada.
Karen DallasFaculty of Medicine, University of British Columbia, Vancouver, BC V6T 1Z4, Canada.
Khaled RamadanFaculty of Medicine, University of British Columbia, Vancouver, BC V6T 1Z4, Canada.
Hayley MerkeleyFaculty of Medicine, University of British Columbia, Vancouver, BC V6T 1Z4, Canada.
Heather LeitchFaculty of Medicine, University of British Columbia, Vancouver, BC V6T 1Z4, Canada.
Yasser Abou MouradFaculty of Medicine, University of British Columbia, Vancouver, BC V6T 1Z4, Canada.
Ryan D CassadayDepartment of Medicine, University of Washington, Seattle, WA 98195, USA.
Camilla RossFaculty of Medicine, University of British Columbia, Vancouver, BC V6T 1Z4, Canada.
Chantal LégerFaculty of Medicine, University of British Columbia, Vancouver, BC V6T 1Z4, Canada.
Providence Health Care · CABC Cancer Agency · CAUniversity of British Columbia · CAUniversity of Washington · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Salvage options for patients with relapsed B-cell acute lymphoblastic leukemia (B-ALL) include inotuzumab ozogamicin (InO), a recombinant, humanized anti-CD22 monoclonal antibody conjugated to the cytotoxic antibiotic calicheamicin. However, the benefit of InO in patients with dim CD22 expression remains unclear. We present a case of a patient with B-ALL who responded to InO despite only dim surface expression of CD22 by flow cytometry, achieving a survival benefit concordant with that reported in the literature and maintaining a good quality of life as a transfusion-independent outpatient. Our observation has broad relevance to clinicians who manage patients with B-ALL who are candidates for InO.

Indexed as

Precursor Cell Lymphoblastic Leukemia-LymphomaQuality of LifeAntibodies, Monoclonal, HumanizedHumansInotuzumab OzogamicinSialic Acid Binding Ig-like Lectin 2Antibodies, Monoclonal, HumanizedCD22 protein, humanInotuzumab OzogamicinSialic Acid Binding Ig-like Lectin 2acute lymphoblastic leukemiacd22flow cytometryimmunotherapyinotuzumab ozogamicin

Identifiers

PMID33704192
PMCPMC7900888
OpenAlexW3113577374

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.